Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

The FDA has announced that Astra-Zeneca Pharmaceuticals has revised the package insert for the cholesterol-lowering drug rosuvastatin (Crestor). The label changes include results from a Phase IV pharmacokinetic study in Asian Ameri-cans and highlight important information on the safe use of rosuvastatin to reduce the risk for serious muscle toxicity (myopathy/rhabdomyolysis), especially at the highest approved dose of 40 mg.

FDA issues public health advisory on rosuvastatin (Crestor)